From: Pirfenidone improves survival in IPF: results from a real-life study
Age | 74.9 ± 11a |
Never smokers | 29 (35.3%) |
Smokers | 53 (64.7%) |
Pack Years | 43.5 ± 32.1a |
Radiological pattern (Definite UIP/Possible UIP) | 47(57.3%)/35(42.7%) |
Advanced disease (DLco< 30%) | 7(8.5%) |
Surgical lung biopsy | 13 (15.9%) |
FEV1% | 87.4 ± 22.7a |
FVC % | 81.5 ± 19.5a |
DLco % | 54.4 ± 17.9a |
Median follow-up time (IQR) | 17.4 months (9.5–30.9). |
Deaths | 15 (18.3%) |